Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Levomilnacipran Hydrochloride Extended-Release Capsules in the Treatment of Patients With Major Depressive Disorder (MDD)

NCT07253207 is registered in ClinicalTrials.gov with Zhejiang Huahai Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07253207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07253207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active-Controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Levomilnacipran Hydrochloride Extended-Release Capsules in the Treatment of Patients With Major Depressive Disorder (MDD)
Lead sponsor
Zhejiang Huahai Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2024
Completion date
July 22, 2025
Enrollment
392 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)